id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0529,FDA,FDA-2007-D-0369,PSG_203858 - Draft Guidance on Lomitapide Mesylate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:16Z,,0,0,0900006484968cb1
FDA-2007-D-0369-0522,FDA,FDA-2007-D-0369,PSG_022563 - Draft Guidance on Calcipotriene,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:14Z,,0,0,0900006484968caa
FDA-2007-D-0369-0526,FDA,FDA-2007-D-0369,PSG_200063 - Draft Guidance on Bupropion Hydrochloride; Naltrexone Hydrochloride,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:15Z,,0,0,0900006484968cae
FDA-2007-D-0369-0513,FDA,FDA-2007-D-0369,PSG_011751 - Draft Guidance on Fluphenazine Hydrochloride,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:11Z,,0,0,0900006484968d7b
FDA-2007-D-0369-0525,FDA,FDA-2007-D-0369,PSG_061904 - Draft Guidance on Erythromycin Ethylsuccinate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:15Z,,0,0,0900006484968cad
FDA-2007-D-0369-0533,FDA,FDA-2007-D-0369,PSG_207071 - Draft Guidance on Azelaic Acid,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:17Z,,0,0,0900006484968cb5
FDA-2007-D-0369-0537,FDA,FDA-2007-D-0369,PSG_208910 - Draft Guidance on Vancomycin Hydrochloride,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:17Z,,0,0,0900006484968cb9
FDA-2007-D-0369-0540,FDA,FDA-2007-D-0369,PSG_211635 - Draft Guidance on Diazepam,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:18Z,,0,0,0900006484968cbc
FDA-2007-D-0369-0514,FDA,FDA-2007-D-0369,PSG_016418 - Draft Guidance on Propranolol Hydrochloride,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:13Z,,0,0,0900006484968d7c
FDA-2007-D-0369-0544,FDA,FDA-2007-D-0369,PSG_212862 - Draft Guidance on Pretomanid,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:20Z,,0,0,0900006484968cc0
FDA-2007-D-0369-0523,FDA,FDA-2007-D-0369,PSG_050207 - Draft Guidance on Erythromycin Ethylsuccinate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:15Z,,0,0,0900006484968cab
FDA-2007-D-0369-0531,FDA,FDA-2007-D-0369,PSG_205777 - Draft Guidance on Naloxone Hydrochloride; Oxycodone Hydrochloride,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:17Z,,0,0,0900006484968cb3
FDA-2007-D-0369-0534,FDA,FDA-2007-D-0369,PSG_207318 - Draft Guidance on Pimavanserin Tartrate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:17Z,,0,0,0900006484968cb6
FDA-2007-D-0369-0543,FDA,FDA-2007-D-0369,PSG_212161 - Draft Guidance on Tafamidis,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:18Z,,0,0,0900006484968cbf
FDA-2007-D-0369-0521,FDA,FDA-2007-D-0369,PSG_022013 - Draft Guidance on Clobetasol Propionate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:14Z,,0,0,0900006484968ca9
FDA-2007-D-0369-0517,FDA,FDA-2007-D-0369,PSG_018662 - Draft Guidance on Isotretinoin,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:14Z,,0,0,0900006484968ca5
FDA-2007-D-0369-0541,FDA,FDA-2007-D-0369,PSG_211672 - Draft Guidance on Lefamulin Acetate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:18Z,,0,0,0900006484968cbd
FDA-2007-D-0369-0530,FDA,FDA-2007-D-0369,PSG_205613 - Draft Guidance on Budesonide,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:16Z,,0,0,0900006484968cb2
FDA-2007-D-0369-0518,FDA,FDA-2007-D-0369,PSG_021438 - Draft Guidance on Propranolol Hydrochloride,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:14Z,,0,0,0900006484968ca6
FDA-2007-D-0369-0520,FDA,FDA-2007-D-0369,PSG_021978 - Draft Guidance on Desonide,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:14Z,,0,0,0900006484968ca8
FDA-2007-D-0369-0510,FDA,FDA-2007-D-0369,"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry;
Availability",Notice,Notice of Availability,2020-11-19T05:00:00Z,2020,11,2020-11-19T05:00:00Z,2021-01-20T04:59:59Z,2020-11-19T14:06:28Z,2020-25602,0,0,09000064849686e1
FDA-2007-D-0369-0519,FDA,FDA-2007-D-0369,PSG_021951 - Draft Guidance on Isotretinoin,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:14Z,,0,0,0900006484968ca7
FDA-2007-D-0369-0539,FDA,FDA-2007-D-0369,PSG_211225 - Draft Guidance on Ceritinib,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:18Z,,0,0,0900006484968cbb
FDA-2007-D-0369-0538,FDA,FDA-2007-D-0369,PSG_210833 - Draft Guidance on Clobazam,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:18Z,,0,0,0900006484968cba
FDA-2007-D-0369-0511,FDA,FDA-2007-D-0369,PSG_008720 - Draft Guidance on Levorphanol Tartrate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:11Z,,0,0,0900006484968d79
FDA-2007-D-0369-0524,FDA,FDA-2007-D-0369,PSG_050529 - Draft Guidance on Erythromycin Ethylsuccinate; Sulfisoxazole Acetyl,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:15Z,,0,0,0900006484968cac
FDA-2007-D-0369-0535,FDA,FDA-2007-D-0369,PSG_207960 - Draft Guidance on Methylphenidate Hydrochloride,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:17Z,,0,0,0900006484968cb7
FDA-2007-D-0369-0542,FDA,FDA-2007-D-0369,PSG_211996 - Draft Guidance on Tafamidis Meglumine,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:18Z,,0,0,0900006484968cbe
FDA-2007-D-0369-0516,FDA,FDA-2007-D-0369,PSG_018553 - Draft Guidance on Propranolol Hydrochloride,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:13Z,,0,0,0900006484968d7e
FDA-2007-D-0369-0527,FDA,FDA-2007-D-0369,PSG_200655 - Draft Guidance on Fluorodopa F-18,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:15Z,,0,0,0900006484968caf
FDA-2007-D-0369-0512,FDA,FDA-2007-D-0369,PSG_010571 - Draft Guidance on Prochlorperazine Maleate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:11Z,,0,0,0900006484968d7a
FDA-2007-D-0369-0528,FDA,FDA-2007-D-0369,PSG_202292 - Draft Guidance on Crofelemer,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:15Z,,0,0,0900006484968cb0
FDA-2007-D-0369-0532,FDA,FDA-2007-D-0369,PSG_205920 - Draft Guidance on Epinephrine,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:17Z,,0,0,0900006484968cb4
FDA-2007-D-0369-0536,FDA,FDA-2007-D-0369,PSG_208246 - Draft Guidance on Tofacitinib Citrate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:17Z,,0,0,0900006484968cb8
FDA-2007-D-0369-0515,FDA,FDA-2007-D-0369,PSG_017351 - Draft Guidance on Hydrocortisone Acetate,Supporting & Related Material,Guidance,2020-11-19T05:00:00Z,2020,11,,,2024-11-06T23:41:13Z,,0,0,0900006484968d7d
FDA-2007-D-0369-0508,FDA,FDA-2007-D-0369,Product-Specific Guidance for Tiotropium Bromide; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2020-11-18T05:00:00Z,2020,11,2020-11-18T05:00:00Z,2021-01-20T04:59:59Z,2021-01-16T02:01:08Z,2020-25412,0,0,09000064849661a3
FDA-2007-D-0369-0509,FDA,FDA-2007-D-0369,Draft Guidance on Tiotropium Bromide,Other,Guidance,2020-11-18T05:00:00Z,2020,11,2020-11-18T05:00:00Z,,2024-11-06T23:40:25Z,,1,0,0900006484965ca1
FDA-2007-D-0369-0502,FDA,FDA-2007-D-0369,"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry;
Availability",Notice,Notice of Availability,2020-08-31T04:00:00Z,2020,8,2020-08-31T04:00:00Z,2020-10-31T03:59:59Z,2020-10-24T01:00:52Z,2020-19164,0,0,090000648482cf4b
FDA-2007-D-0369-0498,FDA,FDA-2007-D-0369,"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry;
Availability",Notice,Notice of Availability,2020-06-04T04:00:00Z,2020,6,2020-06-04T04:00:00Z,2020-08-04T03:59:59Z,2020-08-04T01:01:45Z,2020-12100,0,0,09000064846c9e54
FDA-2007-D-0369-0493,FDA,FDA-2007-D-0369,Product-Specific Guidances; Guidance for Industry; Availability,Notice,Notice of Availability,2020-04-14T04:00:00Z,2020,4,2020-04-14T04:00:00Z,,2024-11-06T23:33:20Z,2020-07751,1,0,09000064844a2653
FDA-2007-D-0369-0484,FDA,FDA-2007-D-0369,"Product-Specific Guidances; Draft and Revised Draft Guidances for Industry;
Availability",Notice,Notice of Availability,2020-03-03T05:00:00Z,2020,3,2020-03-03T05:00:00Z,2020-05-05T03:59:59Z,2020-04-24T01:01:24Z,2020-04320,0,0,09000064843d883c
FDA-2007-D-0369-0482,FDA,FDA-2007-D-0369,Draft Guidance on Levonorgestrel,Other,Guidance,2020-01-23T05:00:00Z,2020,1,2020-01-23T05:00:00Z,2020-03-24T03:59:59Z,2024-11-12T23:15:48Z,,1,0,09000064842dfec7
FDA-2007-D-0369-0481,FDA,FDA-2007-D-0369,Product-Specific Guidance for Levonorgestrel; Intrauterine Device; Revised Draft Guidance for Industry; Availability,Notice,Notice of Availability,2020-01-23T05:00:00Z,2020,1,2020-01-23T05:00:00Z,2020-03-24T03:59:59Z,2020-04-09T17:01:46Z,2020-01072,0,0,09000064842de6de